ArticleMedicine2026
Mendelian randomization analysis links HLA-DR+ CD14- CD16+ monocytes to CCL19-driven ankylosing spondylitis risk.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ankylosing spondylitis (AS), strongly linked to human leukocyte antigen (HLA)-B27, lacks effective treatments for many patients despite biologics. This study investigated causal links between immune cells, inflammatory proteins, and AS to identify new therapeutic targets using genetic methods. Mendelian randomization (MR) analysis was applied using large-scale genetic data. Immune cell data came from Vuckovic et al and Orrù et al, AS data from FinnGen, and inflammatory protein data from Zhao et al. Two-sample MR explored causal relationships, and mediation analysis assessed whether proteins mediated immune cell effects on AS. MR analysis identified 26 immune cell phenotypes associated with AS, with HLA DR+ CD14- CD16+ monocytes showing the strongest protective effect (odds ratio = 0.6423). Among the 5 associated inflammatory proteins, C-C motif chemokine 19 (CCL19) had the most substantial effect on AS risk (odds ratio = 2.4234). Mediation analysis revealed that HLA DR+ CD14- CD16+ monocytes influence AS risk by reducing CCL19 levels, with the proportion of the mediated effect was 17.98% (95% confidence interval = 8.23%-27.72%). Our findings suggest that HLA DR+ CD14- CD16+ monocytes are associated with a reduced risk of AS, as indicated by a negative causal effect (β = -0.4426). This protective effect is partially mediated by a decrease in CCL19 levels, a chemokine that, when elevated, increases AS risk. These results identify CCL19 and this monocyte subset as potential key players in AS pathogenesis and highlight them as promising targets for more effective, personalized therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.